{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009978","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.667814+00:00","generated_at":"2026-06-04T19:32:36.991629+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"RenovoRx promotes Leesa Gentry to CCO; salary $325k, option for 190k shares","bullets":["Leesa Gentry promoted from SVP of Clinical Operations to Chief Clinical Officer, effective March 1, 2024.","Annual base salary of $325,000, with potential increase to $396,000 if CEO salary restored after 2024 reduction.","Eligible for annual discretionary bonus up to 35% of base salary; for 2024 bonus not pro-rated.","Received option to purchase 190,000 shares at $1.69 per share, vesting over 4 years in monthly installments."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009978","json":"https://secwatch.observer/filing/0001493152-24-009978.json","markdown":"https://secwatch.observer/filing/0001493152-24-009978.md","text":"https://secwatch.observer/filing/0001493152-24-009978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/0001493152-24-009978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:32:36.991629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"835f0a1583","claim":"Leesa Gentry was appointed as Chief Clinical Officer at RenovoRx, Inc..","evidence_excerpt":"On February 22, 2024, the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), appointed Leesa Gentry, the Company’s former Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/0001493152-24-009978-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Clinical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}